[Amplification of oncogenes HER2, mdm-2 and myc in breast cancer determined by modified competitive PCR].
The amplification of oncogenes HER2, mdm-2 and myc was determined with a modified competitive PCR. The HER2, mdm-2 and myc genes were found to amplify in 5, 6 and 6 out of 15 patients with breast cancer respectively. The amplification of HER2 and mdm-2 correlated with advanced tumors and lymph node involvement respectively, indicating that the amplification of the oncogenes is a useful indicator for the prognosis of patients with breast cancer and for the study of the biological behaviors of tumors. This modified non-radioactive competitive PCR is simple to handle (even for DNA samples with low quantity and low quality), and accurate for measuring the copy numbers of genes.
Deng
G R
GR
Beijing Institute for Cancer Research.
He
L W
LW
Lu
Y Y
YY
D001483:Base Sequence; D001943:Breast Neoplasms / Q000235:genetics*; D005260:Female; D018734:Genes, erbB-2; D016259:Genes, myc; D006801:Humans; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction / Q000379:methods; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics
D011518:Proto-Oncogene Proteins